• Mabion S.A. and SyVento sp. z o.o. announce the signing of a Letter of Intent to establish cooperation in the manufacturing of a medicinal product. Under the planned collaboration, SyVento will provide aseptic fill and finish services for the drug product on behalf of Mabion, in pre-filled syringe (PFS) and cartridge formats. These fill & finish processes will be carried out under both Good Manufacturing Practice (GMP) conditions and development (non-GMP) conditions – the former for clinical/commercial production and the latter for research and development purposes. In this cooperation model, Mabion will act as the prime contractor overseeing the entire project, while SyVento will serve as a subcontractor responsible for the specialized filling and finishing stages of the product. The partnership framework is designed to cover projects for external clients, with Mabion as the lead contractor towards the client and SyVento as Mabion’s subcontractor,as well as Mabion’s own in-house projects, reflecting the flexibility and complementary expertise of both companies.
  • According to the Letter of Intent, the parties plan to finalize a Master Service Agreement (MSA) by March 31, 2026, and to sign the relevant Statement of Work (SOW) and commence the provision of the agreed services after acquiring a customer. Combining Mabion’s experience as a leading biologics-focused CDMO with SyVento’s cutting-edge fill and finish technologies is expected to accelerate the development of innovative therapies and deliver tangible scientific and business benefits for both parties.

“This initiative is a significant step for SyVento. It allows us to leverage our specialized competencies in aseptic drug product filling and finishing in partnership with an experienced CDMO like Mabion. We are convinced that the synergy between Mabion’s know-how in biologics and our state-of-the-art technologies will yield measurable scientific and business benefits for both sides, ultimately speeding up the introduction of innovative therapies to the market,” said Radosław Kajetan Bartosik, CEO of SyVento sp. z o.o.

“The start of this cooperation is in line with  Mabion’s strategy  of developing comprehensive CDMO services by building partnerships. We are confident that combining our expertise in biologics development with SyVento’s unique capabilities in aseptic fill & finish will significantly enhance the value we deliver to our clients. I believe that this collaboration will become the foundation of a long-term, fruitful partnership between our companies, bringing mutual benefits and contributing to the advancement of the biotech industry in Poland,” added Gregor Kawaletz, CEO of Mabion S.A.

About SyVento sp. z o.o.:
SyVento BioTech is a Polish biotechnology company offering comprehensive services in the research, development, and manufacturing of innovative medicinal products, with a specialization in aseptic filling and formulation processes for drug products in pre-filled syringe (PFS) and cartridge formats. Founded in 2015, SyVento operates a state-of-the-art R&D and production facility in Skawina, Poland, which includes both GMP-compliant sterile production zones and development (non-GMP) laboratories, enabling multiple projects to run in parallel. SyVento is the first company in Poland authorized to independently manufacture, test, and release mRNA-based and lipid nanoparticle (LNP)–based therapies for clinical trials. The company’s mission is to support the advancement of next-generation therapies – from concept through clinical production – by providing integrated CDMO services and platform solutions to pharmaceutical and biotech innovators.

About Mabion S.A.:
Mabion S.A. (WSE: MAB) is a publicly traded Polish biopharmaceutical company, founded in 2007, which underwent a transformation in 2023–2024 into a biologics-focused CDMO (Contract Development and Manufacturing Organization) offering an integrated service portfolio. Mabion specializes in small to mid-sized projects at various stages of development – from early-stage development of stable cell lines to commercial manufacturing. Mabion’s core competencies include monoclonal antibody development technologies, recombinant protein production (using mammalian and insect cell expression systems), advanced analytics, and manufacturing of Drug Substance. The company operates in compliance with globally recognized quality standards, including GMP, GCP, and ISO. Mabion employs over 200 highly qualified professionals, including scientists, engineers, and experts in quality, manufacturing, and analytical development for biologics. Headquartered in the center of Europe, Mabion operates in Poland – an EU member state – providing access to highly regulated markets. The company’s mission is to be a trusted global partner for the development and manufacturing of biologic medicines.

Contact for media and individual investors:

Michał Wierzchowski
+48 531 613 067
michal.wierzchowski@ccgroup.pl

Mardoniusz Maćkowiak
+48 605 959 539
mardoniusz.mackowiak@ccgroup.pl

Contact for institutional investors and analysts:
Piotr Owdziej
+48 697 612 913
piotr.owdziej@ccgroup.pl

Katarzyna Mucha
+48 697 613 712
katarzyna.mucha@ccgroup.pl